Bioanalytical platforms using raman/ftir for neurodegenerative disease diagnosis
Innovative in-vitro diagnostic platforms using Raman and FTIR spectroscopy to identify biomarkers for early diagnosis of neurodegenerative diseases like Alzheimer's, Parkinson's, and ALS. Integrates microfluidic systems for enhanced sensitivity and specificity.
Overview
This solution presents cutting-edge bioanalytical platforms designed for the early diagnosis of neurodegenerative diseases (NDD) such as Alzheimer's, Parkinson's, and ALS. By leveraging Raman and FTIR spectroscopy, these in-vitro diagnostics aim to identify and sort biomarkers, enabling timely interventions. The technology is designed to analyze molecular signatures in biological samples, offering a novel approach to disease identification and monitoring.
Technical specifications
- Integrated Spectroscopic Systems: Combines Raman and FTIR components for comprehensive spectroscopic analysis.
- Microfluidic Platforms: Custom-designed microfluidic devices and chips are optimized for handling biological samples such as blood, cerebrospinal fluid, and saliva.
- Biomarker Identification: Utilizes spectroscopy to detect unique molecular fingerprints associated with NDD.
- Optimization Goals: Focuses on enhancing sensitivity, specificity, and portability for practical clinical use.
- Prototype Testing: Includes rigorous testing and optimization with samples from NDD patients and healthy controls.
Technology readiness level
Currently at Technology Readiness Level 3, this technology involves active research and development with prototype testing and validation efforts underway through collaboration between the University of Leeds, University of Tartu, and associated spin-offs.
About University of Leeds
The University of Leeds is a comprehensive, research‑intensive public university serving a large student body and global partner network. Industry partners engage through an on‑campus innovation hub offering flexible workspace, shared labs and prototyping, and options to co‑locate with academic experts. The university’s integration with major NHS teaching hospitals in the city enables clinical research, validation, and translation. Research is backed by competitive funding from UK Research and Innovation (UKRI) councils and the National Institute for Health and Care Research, with additional European and industry support. A dedicated technology transfer office manages IP, licensing, and spinouts, with partnership models and professional education tailored for corporate R&D.
delivered to your inbox.